2007
Dr. Rosenheck and Colleagues Reply
ROSENHECK R, STROUP T, SWARTZ M, McEVOY J, DAVIS S, KEEFE R, HSIAO J, LIEBERMAN J. Dr. Rosenheck and Colleagues Reply. American Journal Of Psychiatry 2007, 164: 678-680. PMID: 17403984, DOI: 10.1176/ajp.2007.164.4.678a.Peer-Reviewed Original Research
2006
Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia
Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, Perkins DO, Hsiao JK, Lieberman J. Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia. American Journal Of Psychiatry 2006, 163: 2080-2089. PMID: 17151158, DOI: 10.1176/ajp.2006.163.12.2080.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntipsychotic AgentsChronic DiseaseCost-Benefit AnalysisDrug CostsFollow-Up StudiesHealth Care CostsHumansLongitudinal StudiesMiddle AgedPatient DropoutsPerphenazinePsychiatric Status Rating ScalesQuality-Adjusted Life YearsResearch DesignSchizophreniaSchizophrenic PsychologyTreatment Outcome
1995
Clozapine's cost effectiveness.
Rosenheck R, Charney D, Frisman L, Cramer J. Clozapine's cost effectiveness. American Journal Of Psychiatry 1995, 152: 152-3. PMID: 7802113.Peer-Reviewed Original Research